
Emapalumab (em” a pal’ ue mab) is a recombinant, human IgG1 monoclonal antibody to gamma interferon, which inhibits its binding to cell surface interferon receptors and the subsequent activation of intracellular proinflammatory signaling pathways. Gamma interferon levels are known to be elevated in patients with hemophagocytic lymphohistiocytosis (HLH), a life-threatening inflammatory syndrome marked by fever, enlargement of liver and spleen, macrophage update of red blood cells (hemophagocytosis) in bone marrow, spleen and lymph nodes, low natural killer cell activity and high levels of serum ferritin, triglycerides and multiple cytokines.
Emapalumab is an interferon-gamma-blocking antibody used to treat primary hemophagocytic lymphohistiocytosis.
Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon-gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi, and FDA-approved on November 20, 2018.[rx,rx] The approval of emapalumab was followed by the designation of an orphan drug, priority review, and breakthrough therapy.[rx] As well, emapalumab was given the status of PRIME by the EMA.[rx]
Mechanism of action
Emapalumab acts by binding and neutralizing interferon-gamma.[rx] The specific interaction between emapalumab and interferon-gamma produces an inhibition in the interaction between interferon-gamma and its cognate receptor on T-cells which produces the neutralizing activity.[rx] It is important to consider that emapalumab inhibits both free and IFNGR1-bound interferon-gamma as well as the interaction with IFNGR1 and IFNGR2 at the cell surface.[rx]
HLH is an immune dysregulation syndrome in which several cytokines are involved but it has been reported that interferon-gamma plays a pivotal role in the development of this disease as studies have shown a vast increase in the interferon-gamma levels in HLH patients.[rx]
In phase 2/3 clinical trials, emapalumab administered concomitantly with dexamethasone reported an overall response in 63% of the patients. The overall response was defined as the achievement of complete or partial response or HLH improvement.[rx] In this trial and as proof of interferon-gamma neutralization, there was registered a sharp decrease in serum CXCL9 and to avoid QT prolongation in the presence of low doses of emapalumab.[rx]
Indications
- Emapalumab is indicated for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance to conventional HLH therapy.[rx]
- The HLH condition is a hyperinflammatory status characterized by the overwhelming activation of normal T lymphocytes and macrophages which can lead to disturbances in the hematology profile and even death. As part of the condition profile, there have been reports proving a massive overexpression of interferon-gamma which is thought to drive the immune hyperactivation leading to organ failure.[rx] This condition is usually developed and presents the symptomatic profile within the first months or years of life. These symptoms consist of fever, enlarged liver or spleen, and a lower number of blood cells.[rx]
- Progressive, refractory, primary intolerance with conventional therapy, recurrent Hemophagocytic Lymphohistiocytosis
- Emapalumab is used to treat primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy.
- For the treatment of primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy
Use in Cancer
Emapalumab-lzsg is approved to treat:
- Hemophagocytic lymphohistiocytosis (HLH) is inherited. It is used in adults and children (newborn and older) whose disease is refractory (does not respond to treatment), has recurred, has gotten worse, or cannot be treated with other therapies for HLH.
Emapalumab-lzsg is also being studied in the treatment of other conditions.
Contraindications
- active tuberculosis
- shingles
- a type of fungal lung infection called histoplasmosis
- an infection due to a fungus
- pneumonia with a fungus called Pneumocystis jirovecii
Dosage
Strengths: lzsg 5 mg/mL
Histiocytosis
- Initial dose: 1 mg/kg IV over 1 hour 2 times a week (every 3 to 4 days)
- Doses after the initial dose may be increased stepwise to 10 mg/kg based on clinical and laboratory criteria (see Dose Adjustments).
- Duration of therapy: Until hematopoietic stem cell transplantation (HSCT) is performed or unacceptable toxicity; discontinue when a patient no longer requires treatment of HLH.
Premedication/Concomitant Medication:
- For patients who are not receiving baseline dexamethasone: Begin dexamethasone at a daily dose of at least 5 to 10 mg/m2 the day before initiation of this drug.
- For patients who were receiving baseline dexamethasone: They may continue their regular dose provided the dose is at least 5 mg/m2.
- Dexamethasone can be tapered according to the judgment of the physician.
- Test for latent TB using the purified protein derivative (PPD) or IFNy release assay and evaluate patients for TB risk factors.
- Administer TB prophylaxis to patients at risk, or known to have a positive PPD test result or positive IFNy release assay.
- Administer prophylaxis for herpes zoster, Pneumocystis jirovecii, and fungal infections prior to therapy initiation.
- During therapy monitor for TB, adenovirus, EBV, and CMV every 2 weeks and as clinically indicated.
Pediatric Dose for Histiocytosis
- Initial dose: 1 mg/kg IV over 1 hour 2 times a week (every 3 to 4 days)
- Doses after the initial dose may be increased stepwise to 10 mg/kg based on clinical and laboratory criteria (see Dose Adjustments).
- Duration of therapy: Until hematopoietic stem cell transplantation (HSCT) is performed or unacceptable toxicity; discontinue when a patient no longer requires treatment of HLH.
Premedication/Concomitant Medication:
- For patients who are not receiving baseline dexamethasone: Begin dexamethasone at a daily dose of at least 5 to 10 mg/m2 the day before initiation of this drug.
- For patients who were receiving baseline dexamethasone: They may continue their regular dose provided the dose is at least 5 mg/m2.
- Dexamethasone can be tapered according to the judgment of the physician.
- Test for latent TB using the purified protein derivative (PPD) or IFNy release assay and evaluate patients for TB risk factors.
- Administer TB prophylaxis to patients at risk, or known to have a positive PPD test result or positive IFNy release assay.
- Administer prophylaxis for herpes zoster, Pneumocystis jirovecii, and fungal infections prior to therapy initiation.
- During therapy monitor for TB, adenovirus, EBV, and CMV every 2 weeks and as clinically indicated.
Dose Adjustments
Dose Modification Based on Response:
- Day 1: Starting dose of 1 IV mg/kg
- Increase the dose to 3 mg/kg IV on Day 3 for unsatisfactory improvement
- Increase the dose to 6 mg/kg IV on Day 6 onwards for unsatisfactory improvement
- Increase dose to 10 mg/kg IV from Day 9 onwards
NOTE: UNSATISFACTORY IMPROVEMENT ON DAY 3 AND DAY 6 IS DEFINED AS ASSESSED BY A HEALTHCARE PROVIDER AND AT LEAST ONE OF THE FOLLOWING:
FEVER: Persistent or recurring
PLATELET COUNT:
- If the baseline is less than 50,000/mm3 and no improvement to greater than 50,000/mm3
- If the baseline is greater than 50,000/mm3 and less than 30% improvement
- If the baseline is greater than 100,000/mm3 and decreases to less than 100,000/mm3
NEUTROPHIL COUNT:
- If the baseline is less than 500/mm3 and no improvement to greater than 500/mm3
- If a baseline is greater than 500 to 1000/mm3 and decreases to less than 500/mm3 -If the baseline is 1000 to 1500/mm3 and decreases to less than 1000/ mm3
FERRITIN (ng/mL):
- If the baseline is 3000 ng/mL or greater and less than a 20% decrease
- If the baseline is less than 3000 ng/mL and any increase to greater than 3000 ng/mL SPLENOMEGALY: Any worsening
COAGULOPATHY (both D-Dimer and Fibrinogen must apply):
- D-Dimer: If abnormal at baseline and no improvement
- Fibrinogen (mg/dL): If baseline levels are 100 mg/dL or less and no improvement
- If baseline levels are greater than 100 mg/dL) and any decrease to less than 100 mg/dL
NOTE: UNSATISFACTORY IMPROVEMENT ON DAY 9 IS DEFINED AS:
- Assessment by a healthcare provider that based on initial signs of response, a further increase in the dose can be of benefit.
Administration advice:
- Administer diluted solution IV over 1 hour through an IV line containing a sterile, non-pyrogenic, low-protein binding 0.2-micron in-line filter.
- Do not infuse this drug concomitantly with other agents and do not add any other product to the infusion bag or syringe.
Side Effects
The Most Common
- constipation
- nose bleeds
- fast, slow, or irregular heartbeat
- fast breathing
- muscle cramps
- numbness and tingling
- bloody or black, tarry stools
- vomiting blood or brown material that resembles coffee grounds
- decreased urination
- swelling in the hands, feet, ankles, or lower legs
More common
- Agitation
- back pain
- black, tarry stools
- bloating or swelling of the face, arms, hands, lower legs, or feet
- bloody stools
- blurred vision
- chest pain, discomfort, or tightness
- chills
- confusion
- cough
- decreased awareness or responsiveness
- decreased urine
- depression
- difficult or labored breathing
- dry mouth
- fast, pounding, or irregular heartbeat or pulse
- feeling of warmth
- fever
- headache
- hoarseness
- hostility
- increased thirst
- irritability
- lightheadedness, dizziness, or fainting
- loss of appetite
- loss of consciousness
- lower back or side pain
- mood changes
- muscle pain, cramps, or twitching
- nausea
- nervousness
- nosebleed
- numbness or tingling in the hands, feet, or lips
- painful or difficult urination
- pounding in the ears
- rapid weight gain
- rapid, shallow breathing
- redness of the face, neck, arms and occasionally, upper chest
- seizures
- severe sleepiness
- slow heartbeat
- swollen glands
- unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness
- unusual weight gain or loss
- vomiting
- vomiting of blood or material that looks like coffee grounds
Rare
- fever, chills, night sweats;
- loss of appetite, weight loss;
- feeling very tired;
- warmth, redness, or painful sores on your skin;
- cough, trouble breathing;
- mouth and throat ulcers;
- cough with bloody mucus; or
- any other new or worsening signs of infection.
- fever; or
- increased blood pressure.
Drug Interaction
DRUG | INTERACTION |
---|---|
Abatacept | The risk or severity of adverse effects can be increased when Abatacept is combined with Emapalumab. |
Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Emapalumab. |
Abemaciclib | The metabolism of Abemaciclib can be increased when combined with Emapalumab. |
Abrocitinib | The metabolism of Abrocitinib can be increased when combined with Emapalumab. |
Acalabrutinib | The metabolism of Acalabrutinib can be increased when combined with Emapalumab. |
Acebutolol | The metabolism of Acebutolol can be increased when combined with Emapalumab. |
Acenocoumarol | The metabolism of Acenocoumarol can be increased when combined with Emapalumab. |
Acetaminophen | The metabolism of Acetaminophen can be increased when combined with Emapalumab. |
Acetohexamide | The metabolism of Acetohexamide can be increased when combined with Emapalumab. |
Acetylsalicylic acid | The metabolism of Acetylsalicylic acid can be increased when combined with Emapalumab. |
Acyclovir | The metabolism of Acyclovir can be increased when combined with Emapalumab. |
Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Emapalumab. |
Adenovirus type | The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Emapalumab. |
Aducanumab | The risk or severity of adverse effects can be increased when Aducanumab is combined with Emapalumab. |
Agomelatine | The metabolism of Agomelatine can be increased when combined with Emapalumab. |
Albendazole | The metabolism of Albendazole can be increased when combined with Emapalumab. |
Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Emapalumab. |
Alectinib | The metabolism of Alectinib can be increased when combined with Emapalumab. |
Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Emapalumab. |
Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Emapalumab. |
Alfentanil | The metabolism of Alfentanil can be increased when combined with Emapalumab. |
Alirocumab | The risk or severity of adverse effects can be increased when Alirocumab is combined with Emapalumab. |
Allogeneic | The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Emapalumab. |
Almotriptan | The metabolism of Almotriptan can be increased when combined with Emapalumab. |
Alogliptin | The metabolism of Alogliptin can be increased when combined with Emapalumab. |
Alosetron | The metabolism of Alosetron can be increased when combined with Emapalumab. |
Alpelisib | The metabolism of Alpelisib can be increased when combined with Emapalumab. |
Alprazolam | The metabolism of Alprazolam can be increased when combined with Emapalumab. |
Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Emapalumab. |
Ambrisentan | The metabolism of Ambrisentan can be increased when combined with Emapalumab. |
Aminophenazone | The metabolism of Aminophenazone can be increased when combined with Emapalumab. |
Aminophylline | The metabolism of Aminophylline can be increased when combined with Emapalumab. |
Amiodarone | The metabolism of Amiodarone can be increased when combined with Emapalumab. |
Amitriptyline | The metabolism of Amitriptyline can be increased when combined with Emapalumab. |
Amivantamab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Amivantamab. |
Amodiaquine | The metabolism of Amodiaquine can be increased when combined with Emapalumab. |
Amoxapine | The metabolism of Amoxapine can be increased when combined with Emapalumab. |
Amphetamine | The metabolism of Amphetamine can be increased when combined with Emapalumab. |
Amprenavir | The metabolism of Amprenavir can be increased when combined with Emapalumab. |
Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Emapalumab. |
Anagrelide | The metabolism of Anagrelide can be increased when combined with Emapalumab. |
Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Emapalumab. |
Anastrozole | The metabolism of Anastrozole can be increased when combined with Emapalumab. |
Anifrolumab | The risk or severity of adverse effects can be increased when Anifrolumab is combined with Emapalumab. |
Ansuvimab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Ansuvimab. |
Anthrax immune | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Emapalumab. |
Anthrax vaccine | The risk or severity of infection can be increased when Anthrax vaccine is combined with Emapalumab. |
Antilymphocyte | The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Emapalumab. |
Antipyrine | The metabolism of Antipyrine can be increased when combined with Emapalumab. |
Antithymocyte | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Emapalumab. |
Apalutamide | The metabolism of Apalutamide can be increased when combined with Emapalumab. |
Apixaban | The metabolism of Apixaban can be increased when combined with Emapalumab. |
Apomorphine | The metabolism of Apomorphine can be increased when combined with Emapalumab. |
Apremilast | The metabolism of Apremilast can be increased when combined with Emapalumab. |
Aprepitant | The metabolism of Aprepitant can be increased when combined with Emapalumab. |
Arformoterol | The metabolism of Arformoterol can be increased when combined with Emapalumab. |
Aripiprazole | The metabolism of Aripiprazole can be increased when combined with Emapalumab. |
Aripiprazole | The metabolism of Aripiprazole lauroxil can be increased when combined with Emapalumab. |
Arsenic trioxide | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Emapalumab. |
Artemether | The metabolism of Artemether can be increased when combined with Emapalumab. |
Asenapine | The metabolism of Asenapine can be increased when combined with Emapalumab. |
Asfotase alfa | The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Emapalumab. |
Astemizole | The metabolism of Astemizole can be increased when combined with Emapalumab. |
COVID-19 Vaccine | The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Emapalumab. |
Asunaprevir | The metabolism of Asunaprevir can be increased when combined with Emapalumab. |
Atazanavir | The metabolism of Atazanavir can be increased when combined with Emapalumab. |
Atenolol | The metabolism of Atenolol can be increased when combined with Emapalumab. |
Atezolizumab | The risk or severity of adverse effects can be increased when Atezolizumab is combined with Emapalumab. |
Atoltivimab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Atoltivimab. |
Atomoxetine | The metabolism of Atomoxetine can be increased when combined with Emapalumab. |
Atorvastatin | The metabolism of Atorvastatin can be increased when combined with Emapalumab. |
Avanafil | The metabolism of Avanafil can be increased when combined with Emapalumab. |
Avapritinib | The metabolism of Avapritinib can be increased when combined with Emapalumab. |
Avelumab | The risk or severity of adverse effects can be increased when Avelumab is combined with Emapalumab. |
Axitinib | The metabolism of Axitinib can be increased when combined with Emapalumab. |
Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Emapalumab. |
Azathioprine | The metabolism of Azathioprine can be increased when combined with Emapalumab. |
Azelastine | The metabolism of Azelastine can be increased when combined with Emapalumab. |
Azithromycin | The metabolism of Azithromycin can be increased when combined with Emapalumab. |
Bacillus antigen | The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Emapalumab. |
Bacillus | The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Emapalumab. |
Bacillus antigen | The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Emapalumab. |
Bamlanivimab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Bamlanivimab. |
Baricitinib | The risk or severity of adverse effects can be increased when Baricitinib is combined with Emapalumab. |
Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Emapalumab. |
BCG vaccine | The risk or severity of infection can be increased when BCG vaccine is combined with Emapalumab. |
Bebtelovimab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Bebtelovimab. |
Beclomethasone | The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Emapalumab. |
Belantamab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Belantamab mafodotin. |
Belatacept | The risk or severity of adverse effects can be increased when Belatacept is combined with Emapalumab. |
Belimumab | The risk or severity of adverse effects can be increased when Belimumab is combined with Emapalumab. |
Belinostat | The risk or severity of adverse effects can be increased when Belinostat is combined with Emapalumab. |
Belumosudil | The risk or severity of adverse effects can be increased when Emapalumab is combined with Belumosudil. |
Belzutifan | The metabolism of Belzutifan can be increased when combined with Emapalumab. |
Bendamustine | The metabolism of Bendamustine can be increased when combined with Emapalumab. |
Benralizumab | The risk or severity of adverse effects can be increased when Benralizumab is combined with Emapalumab. |
Benzatropine | The metabolism of Benzatropine can be increased when combined with Emapalumab. |
Benzocaine | The metabolism of Benzocaine can be increased when combined with Emapalumab. |
Benzphetamine | The metabolism of Benzphetamine can be increased when combined with Emapalumab. |
Benzyl alcohol | The metabolism of Benzyl alcohol can be increased when combined with Emapalumab. |
Bepridil | The metabolism of Bepridil can be increased when combined with Emapalumab. |
Besilesomab | The risk or severity of adverse effects can be increased when Besilesomab is combined with Emapalumab. |
Betamethasone | The risk or severity of adverse effects can be increased when Betamethasone is combined with Emapalumab. |
Betaxolol | The metabolism of Betaxolol can be increased when combined with Emapalumab. |
Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Emapalumab. |
Bexarotene | The metabolism of Bexarotene can be increased when combined with Emapalumab. |
Bezlotoxumab | The risk or severity of adverse effects can be increased when Bezlotoxumab is combined with Emapalumab. |
Bicalutamide | The metabolism of Bicalutamide can be increased when combined with Emapalumab. |
Bimekizumab | The risk or severity of adverse effects can be increased when Bimekizumab is combined with Emapalumab. |
Binimetinib | The metabolism of Binimetinib can be increased when combined with Emapalumab. |
Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Emapalumab. |
Blinatumomab | The risk or severity of adverse effects can be increased when Blinatumomab is combined with Emapalumab. |
Boceprevir | The metabolism of Boceprevir can be increased when combined with Emapalumab. |
Bordetella | The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Emapalumab. |
Bortezomib | The metabolism of Bortezomib can be increased when combined with Emapalumab. |
Bosentan | The metabolism of Bosentan can be increased when combined with Emapalumab. |
Bosutinib | The metabolism of Bosutinib can be increased when combined with Emapalumab. |
Brentuximab | The metabolism of Brentuximab vedotin can be increased when combined with Emapalumab. |
Brexpiprazole | The metabolism of Brexpiprazole can be increased when combined with Emapalumab. |
Brigatinib | The metabolism of Brigatinib can be increased when combined with Emapalumab. |
Brivaracetam | The metabolism of Brivaracetam can be increased when combined with Emapalumab. |
Brodalumab | The risk or severity of adverse effects can be increased when Brodalumab is combined with Emapalumab. |
Brolucizumab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Brolucizumab. |
Bromazepam | The metabolism of Bromazepam can be increased when combined with Emapalumab. |
Bromotheophylline | The metabolism of Bromotheophylline can be increased when combined with Emapalumab. |
Brompheniramine | The metabolism of Brompheniramine can be increased when combined with Emapalumab. |
Budesonide | The risk or severity of adverse effects can be increased when Budesonide is combined with Emapalumab. |
Bupivacaine | The metabolism of Bupivacaine can be increased when combined with Emapalumab. |
Buprenorphine | The metabolism of Buprenorphine can be increased when combined with Emapalumab. |
Bupropion | The metabolism of Bupropion can be increased when combined with Emapalumab. |
Burosumab | The risk or severity of adverse effects can be increased when Burosumab is combined with Emapalumab. |
Buspirone | The metabolism of Buspirone can be increased when combined with Emapalumab. |
Busulfan | The metabolism of Busulfan can be increased when combined with Emapalumab. |
Cabazitaxel | The metabolism of Cabazitaxel can be increased when combined with Emapalumab. |
Cabergoline | The metabolism of Cabergoline can be increased when combined with Emapalumab. |
Cabozantinib | The metabolism of Cabozantinib can be increased when combined with Emapalumab. |
Caffeine | The metabolism of Caffeine can be increased when combined with Emapalumab. |
Canakinumab | The risk or severity of adverse effects can be increased when Canakinumab is combined with Emapalumab. |
Candesartan cilexetil | The metabolism of Candesartan cilexetil can be increased when combined with Emapalumab. |
Cannabidiol | The metabolism of Cannabidiol can be increased when combined with Emapalumab. |
Capecitabine | The metabolism of Capecitabine can be increased when combined with Emapalumab. |
Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Emapalumab. |
Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Emapalumab. |
Capsaicin | The metabolism of Capsaicin can be increased when combined with Emapalumab. |
Carbamazepine | The metabolism of Carbamazepine can be increased when combined with Emapalumab. |
Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Emapalumab. |
Carfilzomib | The risk or severity of adverse effects can be increased when Carfilzomib is combined with Emapalumab. |
Carisoprodol | The metabolism of Carisoprodol can be increased when combined with Emapalumab. |
Carmustine | The metabolism of Carmustine can be increased when combined with Emapalumab. |
Carvedilol | The metabolism of Carvedilol can be increased when combined with Emapalumab. |
Casirivimab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Casirivimab. |
Catumaxomab | The risk or severity of adverse effects can be increased when Catumaxomab is combined with Emapalumab. |
Celecoxib | The metabolism of Celecoxib can be increased when combined with Emapalumab. |
Celiprolol | The metabolism of Celiprolol can be increased when combined with Emapalumab. |
Cemiplimab | The risk or severity of adverse effects can be increased when Cemiplimab is combined with Emapalumab. |
Cenobamate | The metabolism of Cenobamate can be increased when combined with Emapalumab. |
Cephalexin | The metabolism of Cephalexin can be increased when combined with Emapalumab. |
Ceritinib | The metabolism of Ceritinib can be increased when combined with Emapalumab. |
Cerivastatin | The metabolism of Cerivastatin can be increased when combined with Emapalumab. |
Certolizumab pegol | The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Emapalumab. |
Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Emapalumab. |
Cevimeline | The metabolism of Cevimeline can be increased when combined with Emapalumab. |
Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Emapalumab. |
Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Emapalumab. |
Chloroquine | The metabolism of Chloroquine can be increased when combined with Emapalumab. |
Chlorpheniramine | The metabolism of Chlorpheniramine can be increased when combined with Emapalumab. |
Chlorpromazine | The metabolism of Chlorpromazine can be increased when combined with Emapalumab. |
Chlorpropamide | The metabolism of Chlorpropamide can be increased when combined with Emapalumab. |
Chlorzoxazone | The metabolism of Chlorzoxazone can be increased when combined with Emapalumab. |
Ciclesonide | The metabolism of Ciclesonide can be increased when combined with Emapalumab. |
Cilgavimab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Cilgavimab. |
Cilostazol | The metabolism of Cilostazol can be increased when combined with Emapalumab. |
Cinacalcet | The metabolism of Cinacalcet can be increased when combined with Emapalumab. |
Cinnarizine | The metabolism of Cinnarizine can be increased when combined with Emapalumab. |
Cisapride | The metabolism of Cisapride can be increased when combined with Emapalumab. |
Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Emapalumab. |
Citalopram | The metabolism of Citalopram can be increased when combined with Emapalumab. |
Cladribine | The risk or severity of adverse effects can be increased when Cladribine is combined with Emapalumab. |
Clarithromycin | The metabolism of Clarithromycin can be increased when combined with Emapalumab. |
Clevidipine | The metabolism of Clevidipine can be increased when combined with Emapalumab. |
Clindamycin | The metabolism of Clindamycin can be increased when combined with Emapalumab. |
Clobazam | The metabolism of Clobazam can be increased when combined with Emapalumab. |
Clobetasol | The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Emapalumab. |
Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Emapalumab. |
Clomipramine | The metabolism of Clomipramine can be increased when combined with Emapalumab. |
Clonidine | The metabolism of Clonidine can be increased when combined with Emapalumab. |
Clopidogrel | The metabolism of Clopidogrel can be increased when combined with Emapalumab. |
Clostridium | The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Emapalumab. |
Clotiazepam | The metabolism of Clotiazepam can be increased when combined with Emapalumab. |
Clozapine | The metabolism of Clozapine can be increased when combined with Emapalumab. |
Cobicistat | The metabolism of Cobicistat can be increased when combined with Emapalumab. |
Cobimetinib | The metabolism of Cobimetinib can be increased when combined with Emapalumab. |
Codeine | The metabolism of Codeine can be increased when combined with Emapalumab. |
Conivaptan | The metabolism of Conivaptan can be increased when combined with Emapalumab. |
Conjugated estrogens | The metabolism of Conjugated estrogens can be increased when combined with Emapalumab. |
Copanlisib | The metabolism of Copanlisib can be increased when combined with Emapalumab. |
Corticotropin | The risk or severity of adverse effects can be increased when Corticotropin is combined with Emapalumab. |
Cortisone acetate | The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Emapalumab. |
Corynebacterium | The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Emapalumab. |
Crizotinib | The metabolism of Crizotinib can be increased when combined with Emapalumab |
Cyclobenzaprine | The metabolism of Cyclobenzaprine can be increased when combined with Emapalumab. |
Cyclophosphamide | The metabolism of Cyclophosphamide can be increased when combined with Emapalumab. |
Cyclosporine | Emapalumab may increase the immunosuppressive activities of Cyclosporine. |
Cytarabine | The risk or severity of adverse effects can be increased when Cytarabine is combined with Emapalumab. |
Dabrafenib | The metabolism of Dabrafenib can be increased when combined with Emapalumab. |
Dacarbazine | The metabolism of Dacarbazine can be increased when combined with Emapalumab. |
Daclatasvir | The metabolism of Daclatasvir can be increased when combined with Emapalumab. |
Dacomitinib | The metabolism of Dacomitinib can be increased when combined with Emapalumab. |
Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Emapalumab. |
Dapagliflozin | The metabolism of Dapagliflozin can be increased when combined with Emapalumab. |
Dapsone | The metabolism of Dapsone can be increased when combined with Emapalumab. |
Daratumumab | The risk or severity of adverse effects can be increased when Daratumumab is combined with Emapalumab. |
Darifenacin | The metabolism of Darifenacin can be increased when combined with Emapalumab. |
Dasabuvir | The metabolism of Dasabuvir can be increased when combined with Emapalumab. |
Dasatinib | The metabolism of Dasatinib can be increased when combined with Emapalumab. |
Daunorubicin | The risk or severity of adverse effects can be increased when Daunorubicin is combined with Emapalumab. |
Debrisoquine | The metabolism of Debrisoquine can be increased when combined with Emapalumab. |
Decitabine | The risk or severity of adverse effects can be increased when Decitabine is combined with Emapalumab. |
Deflazacort | The risk or severity of adverse effects can be increased when Deflazacort is combined with Emapalumab. |
Delavirdine | The metabolism of Delavirdine can be increased when combined with Emapalumab. |
Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Emapalumab. |
Desipramine | The metabolism of Desipramine can be increased when combined with Emapalumab. |
Desogestrel | The metabolism of Desogestrel can be increased when combined with Emapalumab. |
Desoximetasone | The risk or severity of adverse effects can be increased when Desoximetasone is combined with Emapalumab. |
Deucravacitinib | The risk or severity of adverse effects can be increased when Emapalumab is combined with Deucravacitinib. |
Deutetrabenazine | The metabolism of Deutetrabenazine can be increased when combined with Emapalumab. |
Dexamethasone | The metabolism of Dexamethasone can be increased when combined with Emapalumab. |
Dexamethasone | The metabolism of Dexamethasone acetate can be increased when combined with Emapalumab. |
Dexchlorpheniramin | The metabolism of Dexchlorpheniramine maleate can be increased when combined with Emapalumab. |
Dexfenfluramine | The metabolism of Dexfenfluramine can be increased when combined with Emapalumab. |
Dexibuprofen | The metabolism of Dexibuprofen can be increased when combined with Emapalumab. |
Dexlansoprazole | The metabolism of Dexlansoprazole can be increased when combined with Emapalumab. |
Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Emapalumab. |
Dextroamphetamine | The metabolism of Dextroamphetamine can be increased when combined with Emapalumab. |
Dextromethorphan | The metabolism of Dextromethorphan can be increased when combined with Emapalumab. |
Dextropropoxyphene | The metabolism of Dextropropoxyphene can be increased when combined with Emapalumab. |
Diazepam | The metabolism of Diazepam can be increased when combined with Emapalumab. |
Diclofenac | The metabolism of Diclofenac can be increased when combined with Emapalumab. |
Dicoumarol | The metabolism of Dicoumarol can be increased when combined with Emapalumab. |
Dienestrol | Dienestrol may increase the thrombogenic activities of Emapalumab. |
Diethylstilbestrol | The metabolism of Diethylstilbestrol can be increased when combined with Emapalumab. |
Difluocortolone | The risk or severity of adverse effects can be increased when Difluocortolone is combined with Emapalumab. |
Digitoxin | The metabolism of Digitoxin can be increased when combined with Emapalumab. |
Digoxin Immune | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Emapalumab. |
Dihydralazine | The metabolism of Dihydralazine can be increased when combined with Emapalumab. |
Dihydrocodeine | The metabolism of Dihydrocodeine can be increased when combined with Emapalumab. |
Dihydroergocornine | The metabolism of Dihydroergocornine can be increased when combined with Emapalumab. |
Dihydroergocristine | The metabolism of Dihydroergocristine can be increased when combined with Emapalumab. |
Dihydroergotamine | The metabolism of Dihydroergotamine can be increased when combined with Emapalumab. |
Diltiazem | The metabolism of Diltiazem can be increased when combined with Emapalumab. |
Dimethyl fumarate | The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Emapalumab. |
Dinutuximab | The risk or severity of adverse effects can be increased when Dinutuximab is combined with Emapalumab. |
Diphenhydramine | The metabolism of Diphenhydramine can be increased when combined with Emapalumab. |
Diroximel | The risk or severity of adverse effects can be increased when Emapalumab is combined with Diroximel fumarate. |
Disopyramide | The metabolism of Disopyramide can be increased when combined with Emapalumab. |
Disulfiram | The metabolism of Disulfiram can be increased when combined with Emapalumab. |
Docetaxel | The metabolism of Docetaxel can be increased when combined with Emapalumab. |
Doconexent | The metabolism of Doconexent can be increased when combined with Emapalumab. |
Dofetilide | The metabolism of Dofetilide can be increased when combined with Emapalumab. |
Dolasetron | The metabolism of Dolasetron can be increased when combined with Emapalumab. |
Domperidone | The metabolism of Domperidone can be increased when combined with Emapalumab. |
Donepezil | The metabolism of Donepezil can be increased when combined with Emapalumab. |
Doravirine | The metabolism of Doravirine can be increased when combined with Emapalumab. |
Dostarlimab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Dostarlimab. |
Dosulepin | The metabolism of Dosulepin can be increased when combined with Emapalumab. |
Doxazosin | The metabolism of Doxazosin can be increased when combined with Emapalumab. |
Doxepin | The metabolism of Doxepin can be increased when combined with Emapalumab. |
Doxorubicin | The metabolism of Doxorubicin can be increased when combined with Emapalumab. |
Dronabinol | The metabolism of Dronabinol can be increased when combined with Emapalumab. |
Dronedarone | The metabolism of Dronedarone can be increased when combined with Emapalumab. |
Drospirenone | The metabolism of Drospirenone can be increased when combined with Emapalumab. |
Dulaglutide | The risk or severity of adverse effects can be increased when Dulaglutide is combined with Emapalumab. |
Duloxetine | The metabolism of Duloxetine can be increased when combined with Emapalumab. |
Dupilumab | The risk or severity of adverse effects can be increased when Dupilumab is combined with Emapalumab. |
Durvalumab | The risk or severity of adverse effects can be increased when Durvalumab is combined with Emapalumab. |
Dutasteride | The metabolism of Dutasteride can be increased when combined with Emapalumab. |
Duvelisib | The metabolism of Duvelisib can be increased when combined with Emapalumab. |
Ebastine | The metabolism of Ebastine can be increased when combined with Emapalumab. |
Ebola Zaire | The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Emapalumab. |
Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Emapalumab. |
Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Emapalumab. |
Efavirenz | The metabolism of Efavirenz can be increased when combined with Emapalumab. |
Eflapegrastim | The risk or severity of adverse effects can be increased when Emapalumab is combined with Eflapegrastim. |
Eftrenonacog alfa | The risk or severity of adverse effects can be increased when Eftrenonacog alfa is combined with Emapalumab. |
Elagolix | The metabolism of Elagolix can be increased when combined with Emapalumab. |
Elbasvir | The metabolism of Elbasvir can be increased when combined with Emapalumab. |
Eletriptan | The metabolism of Eletriptan can be increased when combined with Emapalumab. |
Elexacaftor | The metabolism of Elexacaftor can be increased when combined with Emapalumab. |
Eliglustat | The metabolism of Eliglustat can be increased when combined with Emapalumab. |
Elotuzumab | The risk or severity of adverse effects can be increased when Elotuzumab is combined with Emapalumab. |
Eltrombopag | The metabolism of Eltrombopag can be increased when combined with Emapalumab. |
Emicizumab | The risk or severity of adverse effects can be increased when Emicizumab is combined with Emapalumab. |
Enasidenib | The metabolism of Enasidenib can be increased when combined with Emapalumab. |
Encainide | The metabolism of Encainide can be increased when combined with Emapalumab. |
Encorafenib | The metabolism of Encorafenib can be increased when combined with Emapalumab. |
Enflurane | The metabolism of Enflurane can be increased when combined with Emapalumab. |
Entecavir | The metabolism of Entecavir can be increased when combined with Emapalumab. |
Entrectinib | The metabolism of Entrectinib can be increased when combined with Emapalumab. |
Enzalutamide | The metabolism of Enzalutamide can be increased when combined with Emapalumab. |
Epinastine | The metabolism of Epinastine can be increased when combined with Emapalumab. |
Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Emapalumab. |
Eplerenone | The metabolism of Eplerenone can be increased when combined with Emapalumab. |
Eptinezumab | The risk or severity of adverse effects can be increased when Eptinezumab is combined with Emapalumab. |
Erdafitinib | The metabolism of Erdafitinib can be increased when combined with Emapalumab. |
Erenumab | The risk or severity of adverse effects can be increased when Erenumab is combined with Emapalumab. |
Ergotamine | The metabolism of Ergotamine can be increased when combined with Emapalumab. |
Eribulin | The risk or severity of adverse effects can be increased when Eribulin is combined with Emapalumab. |
Erlotinib | The metabolism of Erlotinib can be increased when combined with Emapalumab. |
Erythromycin | The metabolism of Erythromycin can be increased when combined with Emapalumab. |
Escitalopram | The metabolism of Escitalopram can be increased when combined with Emapalumab. |
Esketamine | The metabolism of Esketamine can be increased when combined with Emapalumab. |
Esmolol | The metabolism of Esmolol can be increased when combined with Emapalumab. |
Esomeprazole | The metabolism of Esomeprazole can be increased when combined with Emapalumab. |
Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Emapalumab. |
Estetrol | The metabolism of Estetrol can be increased when combined with Emapalumab. |
Estradiol | The metabolism of Estradiol can be increased when combined with Emapalumab. |
Estradiol acetate | The metabolism of Estradiol acetate can be increased when combined with Emapalumab. |
Estradiol benzoate | The metabolism of Estradiol benzoate can be increased when combined with Emapalumab. |
Estradiol cypionate | The metabolism of Estradiol cypionate can be increased when combined with Emapalumab. |
Estradiol dienanthate | The metabolism of Estradiol dienanthate can be increased when combined with Emapalumab. |
Estradiol valerate | The metabolism of Estradiol valerate can be increased when combined with Emapalumab. |
Estramustine | The risk or severity of adverse effects can be increased when Estramustine is combined with Emapalumab. |
Estriol | Estriol may increase the thrombogenic activities of Emapalumab. |
Estrone | Estrone may increase the thrombogenic activities of Emapalumab. |
Estrone sulfate | The metabolism of Estrone sulfate can be increased when combined with Emapalumab. |
Eszopiclone | The metabolism of Eszopiclone can be increased when combined with Emapalumab. |
Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Emapalumab. |
Ethanol | The metabolism of Ethanol can be increased when combined with Emapalumab. |
Ethinylestradiol | The metabolism of Ethinylestradiol can be increased when combined with Emapalumab. |
Ethosuximide | The metabolism of Ethosuximide can be increased when combined with Emapalumab. |
Etodolac | The metabolism of Etodolac can be increased when combined with Emapalumab. |
Etoposide | The metabolism of Etoposide can be increased when combined with Emapalumab. |
Etoricoxib | The metabolism of Etoricoxib can be increased when combined with Emapalumab. |
Etravirine | The metabolism of Etravirine can be increased when combined with Emapalumab. |
Everolimus | The metabolism of Everolimus can be increased when combined with Emapalumab. |
Evolocumab | The risk or severity of adverse effects can be increased when Evolocumab is combined with Emapalumab. |
Famtozinameran | The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Emapalumab. |
Fanolesomab | The risk or severity of adverse effects can be increased when Fanolesomab is combined with Emapalumab. |
Fedratinib | The metabolism of Fedratinib can be increased when combined with Emapalumab. |
Felbamate | The metabolism of Felbamate can be increased when combined with Emapalumab. |
Felodipine | The metabolism of Felodipine can be increased when combined with Emapalumab. |
Fenfluramine | The metabolism of Fenfluramine can be increased when combined with Emapalumab. |
Fenofibrate | The metabolism of Fenofibrate can be increased when combined with Emapalumab. |
Fentanyl | The metabolism of Fentanyl can be increased when combined with Emapalumab. |
Fesoterodine | The metabolism of Fesoterodine can be increased when combined with Emapalumab. |
Fexinidazole | The metabolism of Fexinidazole can be increased when combined with Emapalumab. |
Filgotinib | The risk or severity of adverse effects can be increased when Emapalumab is combined with Filgotinib. |
Finasteride | The metabolism of Finasteride can be increased when combined with Emapalumab. |
Finerenone | The metabolism of Finerenone can be increased when combined with Emapalumab. |
Fingolimod | Emapalumab may increase the immunosuppressive activities of Fingolimod. |
Flecainide | The metabolism of Flecainide can be increased when combined with Emapalumab. |
Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Emapalumab. |
Flucytosine | The risk or severity of adverse effects can be increased when Flucytosine is combined with Emapalumab. |
Fludarabine | The risk or severity of adverse effects can be increased when Fludarabine is combined with Emapalumab. |
Fludrocortisone | The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Emapalumab. |
Fluindione | The metabolism of Fluindione can be increased when combined with Emapalumab. |
Flunarizine | The metabolism of Flunarizine can be increased when combined with Emapalumab. |
Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Emapalumab. |
Flunitrazepam | The metabolism of Flunitrazepam can be increased when combined with Emapalumab. |
Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Emapalumab. |
Fluocinonide | The risk or severity of adverse effects can be increased when Fluocinonide is combined with Emapalumab. |
Fluocortolone | The risk or severity of adverse effects can be increased when Fluocortolone is combined with Emapalumab. |
Fluorometholone | The risk or severity of adverse effects can be increased when Fluorometholone is combined with Emapalumab. |
Fluorouracil | The metabolism of Fluorouracil can be increased when combined with Emapalumab. |
Fluoxetine | The metabolism of Fluoxetine can be increased when combined with Emapalumab. |
Fluprednisolone | The risk or severity of adverse effects can be increased when Fluprednisolone is combined with Emapalumab. |
Flurazepam | The metabolism of Flurazepam can be increased when combined with Emapalumab. |
Flurbiprofen | The metabolism of Flurbiprofen can be increased when combined with Emapalumab. |
Flutamide | The metabolism of Flutamide can be increased when combined with Emapalumab. |
Fluticasone | The metabolism of Fluticasone can be increased when combined with Emapalumab. |
Fluticasone | The metabolism of Fluticasone furoate can be increased when combined with Emapalumab. |
Fluticasone propionate | The metabolism of Fluticasone propionate can be increased when combined with Emapalumab. |
Fluvastatin | The metabolism of Fluvastatin can be increased when combined with Emapalumab. |
Fluvoxamine | The metabolism of Fluvoxamine can be increased when combined with Emapalumab. |
Formoterol | The metabolism of Formoterol can be increased when combined with Emapalumab. |
Fosaprepitant | The metabolism of Fosaprepitant can be increased when combined with Emapalumab. |
Fosphenytoin | The metabolism of Fosphenytoin can be increased when combined with Emapalumab. |
Fremanezumab | The risk or severity of adverse effects can be increased when Fremanezumab is combined with Emapalumab. |
Frovatriptan | The metabolism of Frovatriptan can be increased when combined with Emapalumab. |
Fusidic acid | The metabolism of Fusidic acid can be increased when combined with Emapalumab. |
Galantamine | The metabolism of Galantamine can be increased when combined with Emapalumab. |
Galcanezumab | The risk or severity of adverse effects can be increased when Galcanezumab is combined with Emapalumab. |
Gallium nitrate | The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Emapalumab. |
Gefitinib | The metabolism of Gefitinib can be increased when combined with Emapalumab. |
Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Emapalumab. |
Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Emapalumab. |
Gilteritinib | The metabolism of Gilteritinib can be increased when combined with Emapalumab. |
Glasdegib | The metabolism of Glasdegib can be increased when combined with Emapalumab. |
Glatiramer | The risk or severity of adverse effects can be increased when Glatiramer is combined with Emapalumab. |
Gliclazide | The metabolism of Gliclazide can be increased when combined with Emapalumab. |
Glimepiride | The metabolism of Glimepiride can be increased when combined with Emapalumab. |
Glipizide | The metabolism of Glipizide can be increased when combined with Emapalumab. |
Gliquidone | The metabolism of Gliquidone can be increased when combined with Emapalumab. |
Glyburide | The metabolism of Glyburide can be increased when combined with Emapalumab. |
Golimumab | The risk or severity of adverse effects can be increased when Golimumab is combined with Emapalumab. |
Grepafloxacin | The metabolism of Grepafloxacin can be increased when combined with Emapalumab. |
Guanabenz | The metabolism of Guanabenz can be increased when combined with Emapalumab. |
Guselkumab | The risk or severity of adverse effects can be increased when Guselkumab is combined with Emapalumab. |
Haemophilus | The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Emapalumab. |
Halofantrine | The metabolism of Halofantrine can be increased when combined with Emapalumab. |
Hydrocodone | The metabolism of Hydrocodone can be increased when combined with Emapalumab. |
Hydrocortisone | The metabolism of Hydrocortisone can be increased when combined with Emapalumab. |
Hydrocortisone | The metabolism of Hydrocortisone acetate can be increased when combined with Emapalumab. |
Hydrocortisone | The metabolism of Hydrocortisone butyrate can be increased when combined with Emapalumab. |
Hydrocortisone | The metabolism of Hydrocortisone cypionate can be increased when combined with Emapalumab. |
Hydrocortisone | The metabolism of Hydrocortisone phosphate can be increased when combined with Emapalumab. |
Hydrocortisone | The risk or severity of adverse effects can be increased when Hydrocortisone succinate is combined with Emapalumab. |
Hydromorphone | The metabolism of Hydromorphone can be increased when combined with Emapalumab. |
Hydroxychloroquine | The metabolism of Hydroxychloroquine can be increased when combined with Emapalumab. |
Hydroxyprogester | The metabolism of Hydroxyprogesterone caproate can be increased when combined with Emapalumab. |
Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Emapalumab. |
Hydroxyzine | The metabolism of Hydroxyzine can be increased when combined with Emapalumab. |
Ibalizumab | The risk or severity of adverse effects can be increased when Ibalizumab is combined with Emapalumab. |
Ibritumomab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Emapalumab. |
Ibrutinib | The metabolism of Ibrutinib can be increased when combined with Emapalumab. |
Ibuprofen | The metabolism of Ibuprofen can be increased when combined with Emapalumab. |
Idarubicin | The metabolism of Idarubicin can be increased when combined with Emapalumab. |
Idarucizumab | The risk or severity of adverse effects can be increased when Idarucizumab is combined with Emapalumab. |
Idelalisib | The metabolism of Idelalisib can be increased when combined with Emapalumab. |
Ifosfamide | The metabolism of Ifosfamide can be increased when combined with Emapalumab. |
Iloperidone | The metabolism of Iloperidone can be increased when combined with Emapalumab. |
Imatinib | The metabolism of Imatinib can be increased when combined with Emapalumab. |
Imdevimab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Imdevimab. |
Imipramine | The metabolism of Imipramine can be increased when combined with Emapalumab. |
Imlifidase | The therapeutic efficacy of Emapalumab can be decreased when used in combination with Imlifidase. |
Indinavir | The metabolism of Indinavir can be increased when combined with Emapalumab. |
Indomethacin | The metabolism of Indomethacin can be increased when combined with Emapalumab. |
Inebilizumab | The risk or severity of infection can be increased when Emapalumab is combined with Inebilizumab. |
Infigratinib | The metabolism of Infigratinib can be increased when combined with Emapalumab. |
Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Emapalumab. |
Ketorolac | The metabolism of Ketorolac can be increased when combined with Emapalumab. |
Labetalol | The metabolism of Labetalol can be increased when combined with Emapalumab. |
Lacosamide | The metabolism of Lacosamide can be increased when combined with Emapalumab. |
Lanadelumab | The risk or severity of adverse effects can be increased when Lanadelumab is combined with Emapalumab. |
Lansoprazole | The metabolism of Lansoprazole can be increased when combined with Emapalumab. |
Lapatinib | The metabolism of Lapatinib can be increased when combined with Emapalumab. |
Lefamulin | The metabolism of Lefamulin can be increased when combined with Emapalumab. |
Leflunomide | The risk or severity of adverse effects can be increased when Emapalumab is combined with Leflunomide. |
Lemborexant | The metabolism of Lemborexant can be increased when combined with Emapalumab. |
Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Emapalumab. |
Lercanidipine | The metabolism of Lercanidipine can be increased when combined with Emapalumab. |
Lesinurad | The metabolism of Lesinurad can be increased when combined with Emapalumab. |
Letermovir | The metabolism of Letermovir can be increased when combined with Emapalumab. |
Letrozole | The metabolism of Letrozole can be increased when combined with Emapalumab. |
Levacetylmethadol | The metabolism of Levacetylmethadol can be increased when combined with Emapalumab. |
Levamlodipine | The metabolism of Levamlodipine can be increased when combined with Emapalumab. |
Levobetaxolol | The metabolism of Levobetaxolol can be increased when combined with Emapalumab. |
Levobupivacaine | The metabolism of Levobupivacaine can be increased when combined with Emapalumab. |
Levomilnacipran | The metabolism of Levomilnacipran can be increased when combined with Emapalumab. |
Levonorgestrel | The metabolism of Levonorgestrel can be increased when combined with Emapalumab. |
Lidocaine | The metabolism of Lidocaine can be increased when combined with Emapalumab. |
Linagliptin | The metabolism of Linagliptin can be increased when combined with Emapalumab. |
Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Emapalumab. |
Lisuride | The metabolism of Lisuride can be increased when combined with Emapalumab. |
Lofexidine | The metabolism of Lofexidine can be increased when combined with Emapalumab. |
Lomefloxacin | The metabolism of Lomefloxacin can be increased when combined with Emapalumab. |
Lomitapide | The metabolism of Lomitapide can be increased when combined with Emapalumab. |
Lomustine | The risk or severity of adverse effects can be increased when Lomustine is combined with Emapalumab. |
Lonafarnib | The metabolism of Lonafarnib can be increased when combined with Emapalumab. |
Loncastuximab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Loncastuximab tesirine. |
Loperamide | The metabolism of Loperamide can be increased when combined with Emapalumab. |
Lopinavir | The serum concentration of Emapalumab can be increased when it is combined with Lopinavir. |
Lorcaserin | The metabolism of Lorcaserin can be increased when combined with Emapalumab. |
Lorlatinib | The metabolism of Lorlatinib can be increased when combined with Emapalumab. |
Lornoxicam | The metabolism of Lornoxicam can be increased when combined with Emapalumab. |
Lorpiprazole | The metabolism of Lorpiprazole can be increased when combined with Emapalumab. |
Losartan | The metabolism of Losartan can be increased when combined with Emapalumab. |
Lovastatin | The metabolism of Lovastatin can be increased when combined with Emapalumab. |
Lumiracoxib | The metabolism of Lumiracoxib can be increased when combined with Emapalumab. |
Lynestrenol | The metabolism of Lynestrenol can be increased when combined with Emapalumab. |
Maftivimab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Maftivimab. |
Magnesium | The serum concentration of Magnesium can be decreased when it is combined with Emapalumab. |
Maprotiline | The metabolism of Maprotiline can be increased when combined with Emapalumab. |
Margetuximab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Margetuximab. |
Mavacamten | The metabolism of Mavacamten can be increased when combined with Emapalumab. |
Measles attenuated | The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Emapalumab. |
Mechlorethamine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Emapalumab. |
Meclizine | The metabolism of Meclizine can be increased when combined with Emapalumab. |
Mefenamic acid | The metabolism of Mefenamic acid can be increased when combined with Emapalumab. |
Melatonin | The metabolism of Melatonin can be increased when combined with Emapalumab. |
Meloxicam | The metabolism of Meloxicam can be increased when combined with Emapalumab. |
Melphalan | The risk or severity of adverse effects can be increased when Melphalan is combined with Emapalumab. |
Meningococcal | The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Emapalumab. |
Meperidine | The metabolism of Meperidine can be increased when combined with Emapalumab. |
Mephenytoin | The metabolism of Mephenytoin can be increased when combined with Emapalumab. |
Mepolizumab | The risk or severity of adverse effects can be increased when Mepolizumab is combined with Emapalumab. |
Meprednisone | The risk or severity of adverse effects can be increased when Meprednisone is combined with Emapalumab. |
Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Emapalumab. |
Mesoridazine | The metabolism of Mesoridazine can be increased when combined with Emapalumab. |
Mestranol | The metabolism of Mestranol can be increased when combined with Emapalumab. |
Metamfetamine | The metabolism of Metamfetamine can be increased when combined with Emapalumab. |
Methadone | The metabolism of Methadone can be increased when combined with Emapalumab. |
Methimazole | The risk or severity of adverse effects can be increased when Methimazole is combined with Emapalumab. |
Methotrexate | The metabolism of Methotrexate can be increased when combined with Emapalumab. |
Methotrimeprazine | The metabolism of Methotrimeprazine can be increased when combined with Emapalumab. |
Methoxyflurane | The metabolism of Methoxyflurane can be increased when combined with Emapalumab. |
Methsuximide | The metabolism of Methsuximide can be increased when combined with Emapalumab. |
Methylene blue | The metabolism of Methylene blue can be increased when combined with Emapalumab. |
Methylphenobarbital | The metabolism of Methylphenobarbital can be increased when combined with Emapalumab. |
Methylprednisolone | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Emapalumab. |
Methylprednisone | The metabolism of Methylprednisone can be increased when combined with Emapalumab. |
Methyltestosterone | The metabolism of Methyltestosterone can be increased when combined with Emapalumab. |
Methysergide | The metabolism of Methysergide can be increased when combined with Emapalumab. |
Metoclopramide | The metabolism of Metoclopramide can be increased when combined with Emapalumab. |
Metoprolol | The metabolism of Metoprolol can be increased when combined with Emapalumab. |
Metronidazole | The metabolism of Metronidazole can be increased when combined with Emapalumab. |
Mexiletine | The metabolism of Mexiletine can be increased when combined with Emapalumab. |
Mianserin | The metabolism of Mianserin can be increased when combined with Emapalumab. |
Midazolam | The metabolism of Midazolam can be increased when combined with Emapalumab. |
Midostaurin | The metabolism of Midostaurin can be increased when combined with Emapalumab. |
Mifepristone | The metabolism of Mifepristone can be increased when combined with Emapalumab. |
Minaprine | The metabolism of Minaprine can be increased when combined with Emapalumab. |
Mirabegron | The metabolism of Mirabegron can be increased when combined with Emapalumab. |
Mirtazapine | The metabolism of Mirtazapine can be increased when combined with Emapalumab. |
Mirvetuximab | The risk or severity of adverse effects can be increased when Mirvetuximab Soravtansine is combined with Emapalumab. |
Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Emapalumab. |
Mitoxantrone | The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Emapalumab. |
Mobocertinib | The metabolism of Mobocertinib can be increased when combined with Emapalumab. |
Moclobemide | The metabolism of Moclobemide can be increased when combined with Emapalumab. |
Modafinil | The metabolism of Modafinil can be increased when combined with Emapalumab. |
COVID-19 Vaccine | The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Emapalumab. |
Modified vaccinia | The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Emapalumab. |
Mogamulizumab | The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Emapalumab. |
Mometasone furoate | The risk or severity of adverse effects can be increased when Mometasone furoate is combined with Emapalumab. |
Monomethyl | The risk or severity of adverse effects can be increased when Monomethyl fumarate is combined with Emapalumab. |
Montelukast | The metabolism of Montelukast can be increased when combined with Emapalumab. |
Morphine | The metabolism of Morphine can be increased when combined with Emapalumab. |
Mosunetuzumab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Mosunetuzumab. |
Mumps antigen | The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Emapalumab. |
Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Emapalumab. |
Mycophenolate | The metabolism of Mycophenolate mofetil can be increased when combined with Emapalumab. |
Mycophenolic | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Emapalumab. |
Nabilone | The metabolism of Nabilone can be increased when combined with Emapalumab. |
Nabumetone | The metabolism of Nabumetone can be increased when combined with Emapalumab. |
Nadolol | The metabolism of Nadolol can be increased when combined with Emapalumab. |
Naproxen | The metabolism of Naproxen can be increased when combined with Emapalumab. |
Natalizumab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Natalizumab. |
Nateglinide | The metabolism of Nateglinide can be increased when combined with Emapalumab. |
Nebivolol | The metabolism of Nebivolol can be increased when combined with Emapalumab. |
Necitumumab | The risk or severity of adverse effects can be increased when Necitumumab is combined with Emapalumab. |
Nefazodone | The metabolism of Nefazodone can be increased when combined with Emapalumab. |
Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Emapalumab. |
Neratinib | The metabolism of Neratinib can be increased when combined with Emapalumab. |
Netupitant | The metabolism of Netupitant can be increased when combined with Emapalumab. |
Nevirapine | The metabolism of Nevirapine can be increased when combined with Emapalumab. |
Nicardipine | The metabolism of Nicardipine can be increased when combined with Emapalumab. |
Nicergoline | The metabolism of Nicergoline can be increased when combined with Emapalumab. |
Niclosamide | The metabolism of Niclosamide can be increased when combined with Emapalumab. |
Nicotine | The metabolism of Nicotine can be increased when combined with Emapalumab. |
Nifedipine | The metabolism of Nifedipine can be increased when combined with Emapalumab. |
Nilotinib | The metabolism of Nilotinib can be increased when combined with Emapalumab. |
Nilutamide | The metabolism of Nilutamide can be increased when combined with Emapalumab. |
Nilvadipine | The metabolism of Nilvadipine can be increased when combined with Emapalumab. |
Nintedanib | The metabolism of Nintedanib can be increased when combined with Emapalumab. |
Nisoldipine | The metabolism of Nisoldipine can be increased when combined with Emapalumab. |
Nitrendipine | The metabolism of Nitrendipine can be increased when combined with Emapalumab. |
Nivolumab | The risk or severity of adverse effects can be increased when Nivolumab is combined with Emapalumab. |
Norethisterone | The metabolism of Norethisterone can be increased when combined with Emapalumab. |
Norgestimate | The metabolism of Norgestimate can be increased when combined with Emapalumab. |
Nortriptyline | The metabolism of Nortriptyline can be increased when combined with Emapalumab. |
Nuvaxovid | The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Emapalumab. |
Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Emapalumab. |
Obinutuzumab | The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Emapalumab. |
Ocrelizumab | Ocrelizumab may increase the immunosuppressive activities of Emapalumab. |
Odesivimab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Odesivimab. |
Ofatumumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Emapalumab. |
Olanzapine | The metabolism of Olanzapine can be increased when combined with Emapalumab. |
Olaparib | The metabolism of Olaparib can be increased when combined with Emapalumab. |
Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Emapalumab. |
Oliceridine | The metabolism of Oliceridine can be increased when combined with Emapalumab. |
Olodaterol | The metabolism of Olodaterol can be increased when combined with Emapalumab. |
Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Emapalumab. |
Ombitasvir | The metabolism of Ombitasvir can be increased when combined with Emapalumab. |
Omeprazole | The metabolism of Omeprazole can be increased when combined with Emapalumab. |
Ondansetron | The metabolism of Ondansetron can be increased when combined with Emapalumab. |
Opium | The metabolism of Opium can be increased when combined with Emapalumab. |
Osilodrostat | The metabolism of Osilodrostat can be increased when combined with Emapalumab. |
Osimertinib | The metabolism of Osimertinib can be increased when combined with Emapalumab. |
Ospemifene | The metabolism of Ospemifene can be increased when combined with Emapalumab. |
Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Emapalumab. |
Oxprenolol | The metabolism of Oxprenolol can be increased when combined with Emapalumab. |
Oxtriphylline | The metabolism of Oxtriphylline can be increased when combined with Emapalumab. |
Oxybutynin | The metabolism of Oxybutynin can be increased when combined with Emapalumab. |
Oxycodone | The metabolism of Oxycodone can be increased when combined with Emapalumab. |
Oxymorphone | The metabolism of Oxymorphone can be increased when combined with Emapalumab. |
Ozanimod | The risk or severity of adverse effects can be increased when Ozanimod is combined with Emapalumab. |
Paclitaxel | The metabolism of Paclitaxel can be increased when combined with Emapalumab. |
Palbociclib | The metabolism of Palbociclib can be increased when combined with Emapalumab. |
Paliperidone | The metabolism of Paliperidone can be increased when combined with Emapalumab. |
Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Emapalumab. |
Palonosetron | The metabolism of Palonosetron can be increased when combined with Emapalumab. |
Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Emapalumab. |
Panobinostat | The metabolism of Panobinostat can be increased when combined with Emapalumab. |
Pantoprazole | The metabolism of Pantoprazole can be increased when combined with Emapalumab. |
Paramethadione | The metabolism of Paramethadione can be increased when combined with Emapalumab. |
Parecoxib | The metabolism of Parecoxib can be increased when combined with Emapalumab. |
Paritaprevir | The metabolism of Paritaprevir can be increased when combined with Emapalumab. |
Paroxetine | The metabolism of Paroxetine can be increased when combined with Emapalumab. |
Pazopanib | The metabolism of Pazopanib can be increased when combined with Emapalumab. |
Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Emapalumab. |
Pegcetacoplan | The risk or severity of adverse effects can be increased when Emapalumab is combined with Pegcetacoplan. |
Peginterferon | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Emapalumab. |
Peginterferon | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Emapalumab. |
Peginterferon | The risk or severity of adverse effects can be increased when Peginterferon beta-1a is combined with Emapalumab. |
Pembrolizumab | The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Emapalumab. |
Pemetrexed | The metabolism of Pemetrexed can be increased when combined with Emapalumab. |
Penbutolol | The metabolism of Penbutolol can be increased when combined with Emapalumab. |
Penciclovir | The metabolism of Penciclovir can be increased when combined with Emapalumab. |
Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Emapalumab. |
Pentamidine | The metabolism of Pentamidine can be increased when combined with Emapalumab. |
Pentobarbital | The metabolism of Pentobarbital can be increased when combined with Emapalumab. |
Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Emapalumab. |
Pentoxifylline | The metabolism of Pentoxifylline can be increased when combined with Emapalumab. |
Perampanel | The metabolism of Perampanel can be increased when combined with Emapalumab. |
Perhexiline | The metabolism of Perhexiline can be increased when combined with Emapalumab. |
Perphenazine | The metabolism of Perphenazine can be increased when combined with Emapalumab. |
Pertussis vaccine | The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Emapalumab. |
Pertuzumab | The risk or severity of adverse effects can be increased when Pertuzumab is combined with Emapalumab. |
Pexidartinib | The metabolism of Pexidartinib can be increased when combined with Emapalumab. |
Phenformin | The metabolism of Phenformin can be increased when combined with Emapalumab. |
Phenobarbital | The metabolism of Phenobarbital can be increased when combined with Emapalumab. |
Phenprocoumon | The metabolism of Phenprocoumon can be increased when combined with Emapalumab. |
Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Emapalumab. |
Phenylbutazone | The metabolism of Phenylbutazone can be increased when combined with Emapalumab. |
Phenytoin | The metabolism of Phenytoin can be increased when combined with Emapalumab. |
Pimavanserin | The metabolism of Pimavanserin can be increased when combined with Emapalumab. |
Pimecrolimus | The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Emapalumab. |
Pimozide | The metabolism of Pimozide can be increased when combined with Emapalumab. |
Pindolol | The metabolism of Pindolol can be increased when combined with Emapalumab. |
Pioglitazone | The metabolism of Pioglitazone can be increased when combined with Emapalumab. |
Piperaquine | The metabolism of Piperaquine can be increased when combined with Emapalumab. |
Piperazine | The metabolism of Piperazine can be increased when combined with Emapalumab. |
Pipotiazine | The metabolism of Pipotiazine can be increased when combined with Emapalumab. |
Pirfenidone | The metabolism of Pirfenidone can be increased when combined with Emapalumab. |
Piroxicam | The metabolism of Piroxicam can be increased when combined with Emapalumab. |
Pitavastatin | The metabolism of Pitavastatin can be increased when combined with Emapalumab. |
Pitolisant | The metabolism of Pitolisant can be increased when combined with Emapalumab. |
Polatuzumab | The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Emapalumab. |
Polyestradiol | Polyestradiol phosphate may increase the thrombogenic activities of Emapalumab. |
Pomalidomide | The metabolism of Pomalidomide can be increased when combined with Emapalumab. |
Ponatinib | The metabolism of Ponatinib can be increased when combined with Emapalumab. |
Ponesimod | The metabolism of Ponesimod can be increased when combined with Emapalumab. |
Practolol | The metabolism of Practolol can be increased when combined with Emapalumab. |
Pralatrexate | The risk or severity of adverse effects can be increased when Pralatrexate is combined with Emapalumab. |
Prasugrel | The metabolism of Prasugrel can be increased when combined with Emapalumab. |
Praziquantel | The metabolism of Praziquantel can be increased when combined with Emapalumab. |
Prednisolone | The risk or severity of adverse effects can be increased when Prednisolone is combined with Emapalumab. |
Prednisone | The risk or severity of adverse effects can be increased when Prednisone is combined with Emapalumab. |
Pretomanid | The metabolism of Pretomanid can be increased when combined with Emapalumab. |
Primaquine | The metabolism of Primaquine can be increased when combined with Emapalumab. |
Primidone | The metabolism of Primidone can be increased when combined with Emapalumab. |
Procainamide | The metabolism of Procainamide can be increased when combined with Emapalumab. |
Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Emapalumab. |
Prochlorperazine | The metabolism of Prochlorperazine can be increased when combined with Emapalumab. |
Progesterone | The metabolism of Progesterone can be increased when combined with Emapalumab. |
Proguanil | The metabolism of Proguanil can be increased when combined with Emapalumab. |
Promazine | The metabolism of Promazine can be increased when combined with Emapalumab. |
Promethazine | The metabolism of Promethazine can be increased when combined with Emapalumab. |
Propafenone | The metabolism of Propafenone can be increased when combined with Emapalumab. |
Propofol | The metabolism of Propofol can be increased when combined with Emapalumab. |
Propranolol | The metabolism of Propranolol can be increased when combined with Emapalumab. |
Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Emapalumab. |
Quazepam | The metabolism of Quazepam can be increased when combined with Emapalumab. |
Quetiapine | The metabolism of Quetiapine can be increased when combined with Emapalumab. |
Quinestrol | Quinestrol may increase the thrombogenic activities of Emapalumab. |
Quinidine | The metabolism of Quinidine can be increased when combined with Emapalumab. |
Quinine | The metabolism of Quinine can be increased when combined with Emapalumab. |
Rabeprazole | The metabolism of Rabeprazole can be increased when combined with Emapalumab. |
Rabies immune | The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Emapalumab. |
R antigen, A | The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Emapalumab. |
R antigen, B | The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Emapalumab. |
Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Emapalumab. |
Ramelteon | The metabolism of Ramelteon can be increased when combined with Emapalumab. |
Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Emapalumab. |
Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Emapalumab. |
Ranitidine | The metabolism of Ranitidine can be increased when combined with Emapalumab. |
Ranolazine | The metabolism of Ranolazine can be increased when combined with Emapalumab. |
Rasagiline | The metabolism of Rasagiline can be increased when combined with Emapalumab. |
Ravulizumab | The risk or severity of adverse effects can be increased when Ravulizumab is combined with Emapalumab. |
Raxibacumab | The risk or severity of adverse effects can be increased when Raxibacumab is combined with Emapalumab. |
Regorafenib | The metabolism of Regorafenib can be increased when combined with Emapalumab. |
Relugolix | The metabolism of Relugolix can be increased when combined with Emapalumab. |
Remoxipride | The metabolism of Remoxipride can be increased when combined with Emapalumab. |
Repaglinide | The metabolism of Repaglinide can be increased when combined with Emapalumab. |
Reslizumab | The risk or severity of adverse effects can be increased when Reslizumab is combined with Emapalumab. |
Revefenacin | The metabolism of Revefenacin can be increased when combined with Emapalumab. |
Ribociclib | The metabolism of Ribociclib can be increased when combined with Emapalumab. |
Rilonacept | The risk or severity of adverse effects can be increased when Rilonacept is combined with Emapalumab. |
Rilpivirine | The metabolism of Rilpivirine can be increased when combined with Emapalumab. |
Riluzole | The metabolism of Riluzole can be increased when combined with Emapalumab. |
Riociguat | The metabolism of Riociguat can be increased when combined with Emapalumab. |
Risankizumab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Risankizumab. |
Risperidone | The metabolism of Risperidone can be increased when combined with Emapalumab. |
Ritonavir | The metabolism of Ritonavir can be increased when combined with Emapalumab. |
Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Emapalumab. |
Rivaroxaban | The metabolism of Rivaroxaban can be increased when combined with Emapalumab. |
Rofecoxib | The metabolism of Rofecoxib can be increased when combined with Emapalumab. |
Roflumilast | Roflumilast may increase the immunosuppressive activities of Emapalumab. |
Romidepsin | The metabolism of Romidepsin can be increased when combined with Emapalumab. |
Romosozumab | The risk or severity of adverse effects can be increased when Romosozumab is combined with Emapalumab. |
Ropeginterferon | The risk or severity of adverse effects can be increased when Emapalumab is combined with Ropeginterferon alfa-2b. |
Ropinirole | The metabolism of Ropinirole can be increased when combined with Emapalumab. |
Ropivacaine | The metabolism of Ropivacaine can be increased when combined with Emapalumab. |
Rosiglitazone | The metabolism of Rosiglitazone can be increased when combined with Emapalumab. |
Rosuvastatin | The metabolism of Rosuvastatin can be increased when combined with Emapalumab. |
Rotavirus vaccine | The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Emapalumab. |
Rotigotine | The metabolism of Rotigotine can be increased when combined with Emapalumab. |
Roxadustat | The metabolism of Roxadustat can be increased when combined with Emapalumab. |
Rubella virus vaccine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Emapalumab. |
Rucaparib | The metabolism of Rucaparib can be increased when combined with Emapalumab. |
Rupatadine | The metabolism of Rupatadine can be increased when combined with Emapalumab. |
Ruxolitinib | The metabolism of Ruxolitinib can be increased when combined with Emapalumab. |
Sacituzumab | The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Emapalumab. |
Salicylic acid | The metabolism of Salicylic acid can be increased when combined with Emapalumab. |
Salmeterol | The metabolism of Salmeterol can be increased when combined with Emapalumab. |
Saquinavir | The metabolism of Saquinavir can be increased when combined with Emapalumab. |
Sarilumab | The risk or severity of adverse effects can be increased when Sarilumab is combined with Emapalumab. |
Satralizumab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Satralizumab. |
Saxagliptin | The metabolism of Saxagliptin can be increased when combined with Emapalumab. |
Secukinumab | The risk or severity of adverse effects can be increased when Secukinumab is combined with Emapalumab. |
Selegiline | The metabolism of Selegiline can be increased when combined with Emapalumab. |
Selexipag | The metabolism of Selexipag can be increased when combined with Emapalumab. |
Selumetinib | The metabolism of Selumetinib can be increased when combined with Emapalumab. |
Sertindole | The metabolism of Sertindole can be increased when combined with Emapalumab. |
Sertraline | The metabolism of Sertraline can be increased when combined with Emapalumab. |
Sevoflurane | The metabolism of Sevoflurane can be increased when combined with Emapalumab. |
Sildenafil | The metabolism of Sildenafil can be increased when combined with Emapalumab. |
Siltuximab | The risk or severity of adverse effects can be increased when Siltuximab is combined with Emapalumab. |
Simvastatin | The metabolism of Simvastatin can be increased when combined with Emapalumab. |
Siponimod | The metabolism of Siponimod can be increased when combined with Emapalumab. |
Sipuleucel-T | The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Emapalumab. |
Sirolimus | The metabolism of Sirolimus can be increased when combined with Emapalumab. |
Sitagliptin | The metabolism of Sitagliptin can be increased when combined with Emapalumab. |
Sitaxentan | The metabolism of Sitaxentan can be increased when combined with Emapalumab. |
Smallpox | The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Emapalumab. |
Solifenacin | The metabolism of Solifenacin can be increased when combined with Emapalumab. |
Sonidegib | The metabolism of Sonidegib can be increased when combined with Emapalumab. |
Sorafenib | The metabolism of Sorafenib can be increased when combined with Emapalumab. |
Sotalol | The metabolism of Sotalol can be increased when combined with Emapalumab. |
Sotrovimab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Sotrovimab. |
Spesolimab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Spesolimab. |
St. John’s Wort | The metabolism of St. John’s Wort can be increased when combined with Emapalumab. |
Stiripentol | The metabolism of Stiripentol can be increased when combined with Emapalumab. |
Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Emapalumab. |
Sulesomab | The risk or severity of adverse effects can be increased when Sulesomab is combined with Emapalumab. |
Sulfadiazine | The metabolism of Sulfadiazine can be increased when combined with Emapalumab. |
Sulfamethoxazole | The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Emapalumab. |
Sulfasalazine | The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Emapalumab. |
Sunitinib | The metabolism of Sunitinib can be increased when combined with Emapalumab. |
Sutimlimab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Sutimlimab. |
Suvorexant | The metabolism of Suvorexant can be increased when combined with Emapalumab. |
Tacrine | The metabolism of Tacrine can be increased when combined with Emapalumab. |
Tacrolimus | Tacrolimus may increase the immunosuppressive activities of Emapalumab. |
Tadalafil | The metabolism of Tadalafil can be increased when combined with Emapalumab. |
Tafasitamab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Tafasitamab. |
Tafenoquine | The metabolism of Tafenoquine can be increased when combined with Emapalumab. |
Tamoxifen | The metabolism of Tamoxifen can be increased when combined with Emapalumab. |
Tamsulosin | The metabolism of Tamsulosin can be increased when combined with Emapalumab. |
Tasimelteon | The metabolism of Tasimelteon can be increased when combined with Emapalumab. |
Tazarotene | The metabolism of Tazarotene can be increased when combined with Emapalumab. |
Tazemetostat | The metabolism of Tazemetostat can be increased when combined with Emapalumab. |
Tegafur | The metabolism of Tegafur can be increased when combined with Emapalumab. |
Tegafur-uracil | The metabolism of Tegafur-uracil can be increased when combined with Emapalumab. |
Tegaserod | The metabolism of Tegaserod can be increased when combined with Emapalumab. |
Telaprevir | The metabolism of Telaprevir can be increased when combined with Emapalumab. |
Telithromycin | The metabolism of Telithromycin can be increased when combined with Emapalumab. |
Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Emapalumab. |
Temsirolimus | The metabolism of Temsirolimus can be increased when combined with Emapalumab. |
Teniposide | The metabolism of Teniposide can be increased when combined with Emapalumab. |
Tenofovir | The metabolism of Tenofovir alafenamide can be increased when combined with Emapalumab. |
Tenoxicam | The metabolism of Tenoxicam can be increased when combined with Emapalumab. |
Teplizumab | The risk or severity of adverse effects can be increased when Teplizumab is combined with Emapalumab. |
Teprotumumab | The risk or severity of adverse effects can be increased when Teprotumumab is combined with Emapalumab. |
Terbinafine | The metabolism of Terbinafine can be increased when combined with Emapalumab. |
Terfenadine | The metabolism of Terfenadine can be increased when combined with Emapalumab. |
Teriflunomide | The risk or severity of adverse effects can be increased when Teriflunomide is combined with Emapalumab. |
Testosterone | The metabolism of Testosterone can be increased when combined with Emapalumab. |
Testosterone | The metabolism of Testosterone cypionate can be increased when combined with Emapalumab. |
Testosterone | The metabolism of Testosterone enanthate can be increased when combined with Emapalumab. |
Tetanus | The risk or severity of adverse effects can be increased when Tetanus immune globulin, human is combined with Emapalumab. |
Tetrabenazine | The metabolism of Tetrabenazine can be increased when combined with Emapalumab. |
Tezacaftor | The metabolism of Tezacaftor can be increased when combined with Emapalumab. |
Tezepelumab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Tezepelumab. |
Thalidomide | The metabolism of Thalidomide can be increased when combined with Emapalumab. |
Theophylline | The metabolism of Theophylline can be increased when combined with Emapalumab. |
Thiabendazole | The metabolism of Thiabendazole can be increased when combined with Emapalumab. |
Thiamylal | The metabolism of Thiamylal can be increased when combined with Emapalumab. |
Thiopental | The metabolism of Thiopental can be increased when combined with Emapalumab. |
Thioridazine | The metabolism of Thioridazine can be increased when combined with Emapalumab. |
Thiotepa | The metabolism of Thiotepa can be increased when combined with Emapalumab. |
Thiothixene | The metabolism of Thiothixene can be increased when combined with Emapalumab. |
Tibolone | Tibolone may increase the thrombogenic activities of Emapalumab. |
Ticagrelor | The metabolism of Ticagrelor can be increased when combined with Emapalumab. |
Tick-borne | The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Emapalumab. |
Ticlopidine | The metabolism of Ticlopidine can be increased when combined with Emapalumab. |
Tildrakizumab | The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Emapalumab. |
Timolol | The metabolism of Timolol can be increased when combined with Emapalumab. |
Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Emapalumab. |
Tiotropium | The metabolism of Tiotropium can be increased when combined with Emapalumab. |
Tipranavir | The metabolism of Tipranavir can be increased when combined with Emapalumab. |
Tisotumab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Tisotumab vedotin. |
Tixagevimab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Tixagevimab. |
Tixocortol | The risk or severity of adverse effects can be increased when Tixocortol is combined with Emapalumab. |
Tizanidine | The metabolism of Tizanidine can be increased when combined with Emapalumab. |
Tocainide | The metabolism of Tocainide can be increased when combined with Emapalumab. |
Tocilizumab | The risk or severity of adverse effects can be increased when Tocilizumab is combined with Emapalumab. |
Tofacitinib | Emapalumab may increase the immunosuppressive activities of Tofacitinib. |
Tolazamide | The metabolism of Tolazamide can be increased when combined with Emapalumab. |
Tolbutamide | The metabolism of Tolbutamide can be increased when combined with Emapalumab. |
Tolterodine | The metabolism of Tolterodine can be increased when combined with Emapalumab. |
Tolvaptan | The metabolism of Tolvaptan can be increased when combined with Emapalumab. |
Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Emapalumab. |
Torasemide | The metabolism of Torasemide can be increased when combined with Emapalumab. |
Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Emapalumab. |
Trabectedin | The metabolism of Trabectedin can be increased when combined with Emapalumab. |
Tralokinumab | The risk or severity of adverse effects can be increased when Tralokinumab is combined with Emapalumab. |
Tramadol | The metabolism of Tramadol can be increased when combined with Emapalumab. |
Trastuzumab | Trastuzumab may increase the neutropenic activities of Emapalumab. |
Trastuzumab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Trastuzumab deruxtecan. |
Trastuzumab | The metabolism of Trastuzumab emtansine can be increased when combined with Emapalumab. |
Trazodone | The metabolism of Trazodone can be increased when combined with Emapalumab. |
Tremelimumab | The risk or severity of adverse effects can be increased when Tremelimumab is combined with Emapalumab. |
Treprostinil | The metabolism of Treprostinil can be increased when combined with Emapalumab. |
Tretinoin | The metabolism of Tretinoin can be increased when combined with Emapalumab. |
Triamcinolone | The metabolism of Triamcinolone can be increased when combined with Emapalumab. |
Triamterene | The metabolism of Triamterene can be increased when combined with Emapalumab. |
Triazolam | The metabolism of Triazolam can be increased when combined with Emapalumab. |
Triclabendazole | The metabolism of Triclabendazole can be increased when combined with Emapalumab. |
Trifluoperazine | The metabolism of Trifluoperazine can be increased when combined with Emapalumab. |
Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Emapalumab. |
Trilostane | The risk or severity of adverse effects can be increased when Trilostane is combined with Emapalumab. |
Trimethadione | The metabolism of Trimethadione can be increased when combined with Emapalumab. |
Trimethoprim | The metabolism of Trimethoprim can be increased when combined with Emapalumab. |
Trimipramine | The metabolism of Trimipramine can be increased when combined with Emapalumab. |
Troglitazone | The metabolism of Troglitazone can be increased when combined with Emapalumab. |
Tucatinib | The metabolism of Tucatinib can be increased when combined with Emapalumab. |
Typhoid vaccine | The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Emapalumab. |
Typhoid Vaccine | The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Emapalumab. |
Typhoid Vi | The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Emapalumab. |
Udenafil | The metabolism of Udenafil can be increased when combined with Emapalumab. |
Umeclidinium | The metabolism of Umeclidinium can be increased when combined with Emapalumab. |
Upadacitinib | The risk or severity of adverse effects can be increased when Emapalumab is combined with Upadacitinib. |
Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Emapalumab. |
Valentine | The metabolism of Valbenazine can be increased when combined with Emapalumab. |
Valdecoxib | The metabolism of Valdecoxib can be increased when combined with Emapalumab. |
Valproic acid | The metabolism of Valproic acid can be increased when combined with Emapalumab. |
Valsartan | The metabolism of Valsartan can be increased when combined with Emapalumab. |
Vandetanib | The metabolism of Vandetanib can be increased when combined with Emapalumab. |
Vardenafil | The metabolism of Vardenafil can be increased when combined with Emapalumab. |
Pregnancy and Lactation
US FDA pregnancy category: Not assigned.
Pregnancy
The manufacturer makes no recommendation regarding use during pregnancy. There are no available data on the use of this drug in pregnant women to inform a drug-associated risk of adverse developmental outcomes. In animal studies, a murine surrogate anti-mouse antibody administered to pregnant mice throughout gestation crossed the placental barrier, and no fetal harm was observed.
Lactation
Safety has not been established.
Excreted into human milk: Unknown
Excreted into animal milk: Data not available
The effects in the nursing infant are unknown. Available data suggest that only limited amounts of therapeutic antibodies are found in breast milk and they do not enter the neonatal and infant circulations in substantial amounts.
How should this medicine be used?
Emapalumab-lzsg comes as a liquid to be injected into a vein over 1 hour by a doctor or nurse in a hospital or medical facility. It is usually given 2 times per week, every 3 or 4 days, for as long as your doctor recommends that you receive treatment.
Your doctor may start you on a low dose of emapalumab-lzsg injection and gradually increase your dose, not more than once every 3 days.
Emapalumab-lzsg injection may cause a severe reaction during or shortly after the infusion of the medication. A doctor or nurse will monitor you carefully while you are receiving the medication. If you experience any of the following symptoms, tell your doctor immediately: skin redness, itching, fever, rash, excessive sweating, chills, nausea, vomiting, lightheadedness, dizziness, chest pain, or shortness of breath.
Your doctor or pharmacist will give you the manufacturer’s patient information sheet (Medication Guide) when you begin treatment with emapalumab-lzsg injection and each time you receive the medication. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer’s website to obtain the Medication Guide.
What special precautions should I follow?
Before receiving emapalumab-lzsg injection,
- tell your doctor and pharmacist if you are allergic to emapalumab-lzsg, any other medications, or any of the ingredients in emapalumab-lzsg injection. Ask your pharmacist or check the Medication Guide for a list of the ingredients.
- tell your doctor if you have or have ever had any medical condition.
- tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
- tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while receiving emapalumab-lzsg injection, call your doctor.
- you should know that emapalumab-lzsg injection may decrease your ability to fight infection from bacteria, viruses, and fungi and increase the risk that you will get a serious or life-threatening infection. Tell your doctor if you often get any type of infection or if you have or think you may have any type of infection now. This includes minor infections (such as open cuts or sores), infections that come and go (such as herpes or cold sores), and chronic infections that do not go away. If you experience any of the following symptoms during or shortly after your treatment with emapalumab-lzsg injection, call your doctor immediately: fever, sweats, or chills; muscle aches; cough; bloody mucus; shortness of breath; sore throat or difficulty swallowing; warm, red, or painful skin or sores on your body; diarrhea; stomach pain; frequent, urgent, or painful urination; or other signs of infection.
- you should know that receiving emapalumab-lzsg injection increases the risk that you will develop tuberculosis (TB; a serious lung infection), especially if you are already infected with TB but do not have any symptoms of the disease. Tell your doctor if you have or have ever had TB, if you have lived in a country where TB is common, or if you have been around someone who has TB. Your doctor will check you for TB before starting treatment with emapalumab-lzsg injection and may treat you for TB if you have a history of TB or have active TB. If you have any of the following symptoms of TB or if you develop any of these symptoms during your treatment, call your doctor immediately: cough, coughing up blood or mucus, weakness or tiredness, weight loss, loss of appetite, chills, fever, or night sweats.
- do not have any vaccinations without talking to your doctor during your treatment with emapalumab-lzsg injection and for at least 4 weeks after your final dose.
References